Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aidan Foundation | UNKNOWN |
| Neil H. Riordan PhD | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD). The potential muscle regenerative and anti-inflammatory properties of UC MSCs position them as a possible treatment option for DMD. Both of these properties could lead to potential benefits for a DMD patient.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mesenchymal Stem Cells | Experimental | Umbilical Cord Mesenchymal Stem Cells |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Umbilical Cord Mesenchymal Stem Cells | Biological |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events | No occurrence of adverse events | 3 months after final treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline of weight | 3 months after final treatment | |
| Change of muscle diameter (circumferential measurements) from baseline | 3 months after final treatment | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maurice HV Strickland, MD | Allergy and Asthma Consultants of Wichita, KS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asthma and Allergy Consultants | Wichita | Kansas | 67205 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from baseline of Pulmonary Maximum Expiratory Pressure |
| 3 months after final treatment |
| Change from baseline of Pulmonary Forced Vital Capacity | 3 months after final treatment |
| Maximum Change from baseline of Predicted Inspiratory Pressure % | 3 months after final treatment |
| Change from baseline of Predicted Maximum Expiratory Pressure % | 3 months after final treatment |
| Change from baseline of Predicted Forced Vital Capacity % | 3 months after final treatment |
| ID | Term |
|---|---|
| D020388 | Muscular Dystrophy, Duchenne |
| D009136 | Muscular Dystrophies |
| ID | Term |
|---|---|
| D020966 | Muscular Disorders, Atrophic |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D040181 | Genetic Diseases, X-Linked |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided